Evommune (EVMN) Cash & Current Investments (2024 - 2026)

Evommune (EVMN) has 3 years of Cash & Current Investments data on file, last reported at $211.5 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $211.5 million, up 3607.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $211.5 million (up 3607.29% YoY), and the FY2025 annual result was $149.2 million, up 107.11% from the prior year.
• Cash & Current Investments climbed to $211.5 million in Q1 2026 per EVMN's latest filing, from $149.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $211.5 million in Q1 2026 and troughed at $5.7 million in Q1 2025.
• A 3-year average of $88.8 million and a median of $74.1 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments soared 107.11% in 2025, then surged 3607.29% in 2026.
• A 3-year view of Cash & Current Investments shows it stood at $72.0 million in 2024, then soared by 107.11% to $149.2 million in 2025, then jumped by 41.73% to $211.5 million in 2026.
• Business Quant data shows EVMN's Cash & Current Investments at $211.5 million in Q1 2026, $149.2 million in Q4 2025, and $76.1 million in Q3 2025.